Kepler Capital Markets Analysts Give Sartorius (FRA:SRT3) a €128.00 Price Target

Sartorius (FRA:SRT3) has been assigned a €128.00 ($148.84) target price by analysts at Kepler Capital Markets in a research report issued on Tuesday, Borsen Zeitung reports. The firm currently has a “sell” rating on the stock. Kepler Capital Markets’ price target would indicate a potential downside of 28.57% from the company’s previous close.

A number of other analysts have also weighed in on SRT3. Berenberg Bank set a €125.00 ($145.35) price objective on Sartorius and gave the company a “sell” rating in a research note on Thursday, June 6th. Warburg Research set a €162.00 ($188.37) price objective on Sartorius and gave the company a “neutral” rating in a research note on Wednesday, May 15th. HSBC set a €145.00 ($168.60) price objective on Sartorius and gave the company a “neutral” rating in a research note on Monday, May 13th. Nord/LB set a €115.00 ($133.72) price objective on Sartorius and gave the company a “sell” rating in a research note on Tuesday, April 23rd. Finally, UBS Group set a €147.00 ($170.93) price objective on Sartorius and gave the company a “neutral” rating in a research note on Thursday, April 18th. Five analysts have rated the stock with a sell rating and four have assigned a hold rating to the company’s stock. The stock currently has a consensus rating of “Sell” and an average price target of €133.28 ($154.97).

FRA:SRT3 opened at €179.20 ($208.37) on Tuesday. Sartorius has a fifty-two week low of €71.00 ($82.56) and a fifty-two week high of €124.70 ($145.00).



Sartorius Company Profile

Sartorius Aktiengesellschaft supplies pharmaceutical and laboratory equipment worldwide. It operates in two divisions, Bioprocess Solutions, and Lab Products & Services. The company offers products for suspension cell analysis and live-cell analysis inside incubator for oncology, immuno-oncology, antibody discovery, neuroscience, and stem cell research; cell culture media, including antibody and recombinant protein, viral vaccines, and regenerative medicine media, as well as general media and downstream buffers; and multi-parallel, single-use, benchtop, stainless steel, microbial, and cell culture bioreactors, as well as cell culture expansion systems and software applications for bioreactors.

Featured Story: What is Green Investing?

Analyst Recommendations for Sartorius (FRA:SRT3)

Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with MarketBeat.com's FREE daily email newsletter.